Advertisement

Weitere Belege für initiale subkutane Applikation von MTX in der Therapie der rheumatoiden Arthritis gefordert

  • Pontus HartenEmail author
Leserbriefe
  • 39 Downloads

Further evidence necessary for initial subcutaneous administration of MTX in the treatment of rheumatoid arthritis

Notes

Interessenkonflikt

P. Harten gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Braun J, Kästner P, Flaxenberg P et al (2008) Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 58:73–81CrossRefGoogle Scholar
  2. 2.
    De Rotte MC, den Boer E, de Jong PH et al (2015) Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis 74:408–414CrossRefGoogle Scholar
  3. 3.
    Hazlewood GS, Thorne JC, Pope JE et al (2016) The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis 75:1003–1008CrossRefGoogle Scholar
  4. 4.
    Schiff MH, Jaffe JS, Freundlich B et al (2014) Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis 73:1549–1551CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Schwerpunktpraxis internistische RheumatologieKielDeutschland

Personalised recommendations